Nivolumab-relatlimab fixed-dose combination
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Nivolumab-relatlimab fixed-dose combination, covering 2025-08-13 to 2026-08-26. Get the full timeline:
Most recent: Clinical Trial Results: A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer [Phase 3]